BEVERLY, MASSACHUSETTS – September 28, 2022<\/strong> – Quanta Dialysis Technologies\u00ae Ltd (\u201cQuanta\u201d or the \u201cCompany\u201d), a medical technology company committed to making kidney care more accessible with its Quanta\u2122 Dialysis System, today announced that its Board of Directors has unanimously elected Alejandro Galindo, M.B.A., M.S. as the organization\u2019s next chief executive officer (CEO). Mr. Galindo succeeds Interim CEO, Hooman Hakami, who will return to his role on the Board effective November 1, 2022.<\/p>\n\n\n\n \u201cOn behalf of the Board, I am pleased to welcome Alejandro as Quanta\u2019s next CEO,\u201d said Chairman of Quanta\u2019s Board, Johan de Ruiter. \u201cAfter undergoing an extensive search process, we are confident we have the right individual for the role. Alejandro is an inspiring leader. His proven experience driving strategic transformation in the healthcare industry well positions him to accelerate Quanta\u2019s growth and generate value for all of our stakeholders. We also thank Hooman for stepping in as interim CEO during the search, bringing invaluable leadership and ensuring a seamless transition.\u201d<\/p>\n\n\n\n Mr. Galindo joins Quanta with over 25 years of experience in the healthcare, energy and consumer industries. A career veteran known for his considerable expertise across a variety of leadership roles, Mr. Galindo has an accomplished track record in product development, mergers and acquisitions, global expansion, and distribution strategies. Most recently, he served as executive vice president of the Endocrine Business Unit of MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases.<\/p>\n\n\n\n \u201cI appreciate the confidence that the Board has placed in me and am honored to be appointed CEO. We are a purpose-driven organization, dedicated to making dialysis care accessible to every patient in every setting,\u201d said Mr. Galindo. \u201cIt is a privilege for me to join Quanta as it addresses healthcare inequities through the development of transformative innovations which put the patient first. There is tremendous potential in Quanta and I look forward to working with Hooman, the Board, and the executive leadership team \u2013 and learning from our employees, patients, and commercial partners \u2013 as we continue to achieve our vision and lead the company into its next chapter.\u201d<\/p>\n\n\n\n Prior to MannKind, Mr. Galindo spent six years at Medtronic as vice president and president of the Advanced Insulin Management Business Unit, where he achieved double-digit growth within their diabetes division. Mr. Galindo also spent 20 years at General Electric leading teams across the globe from the company\u2019s diverse group of industries. He holds a Master of Science and Master of Business Administration from Indiana University Bloomington and a Bachelor of Science in Engineering from Tecnologico de Monterrey.<\/p>\n","protected":false},"excerpt":{"rendered":" Unanimous Endorsement of MannKind Executive Follows Extensive Search BEVERLY, MASSACHUSETTS – September 28, 2022 – Quanta Dialysis Technologies\u00ae Ltd (\u201cQuanta\u201d or the \u201cCompany\u201d), a medical technology company committed to making kidney care more accessible with its Quanta\u2122 Dialysis System, today announced that its Board of Directors has unanimously elected Alejandro Galindo, M.B.A., M.S. as the […]<\/p>\n","protected":false},"author":1,"featured_media":949,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[7],"tags":[],"class_list":["post-944","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles"],"acf":[],"_links":{"self":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/posts\/944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/comments?post=944"}],"version-history":[{"count":0,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/posts\/944\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/media\/949"}],"wp:attachment":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/media?parent=944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/categories?post=944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/tags?post=944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}